You are here

Our science / Clinical Trials / Find a Trial / NCT00543790

Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

Back to Search Print Save as PDF Bookmark Trial

NCT00543790

Last updated on May 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Beverly Hills, California, 90211 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Uterine Leiomyomata (Fibroids)
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Inclusion Criteria - All Women

- Healthy, nonsmoker or smoker of fewer than 10 cigarettes (half a pack) per day and
able to abstain from tobacco throughout all times when in the clinical facility.

Inclusion Criteria - Cycling Women

- Aged 18 to 45 years, must not be breastfeeding, pregnant, or have a recent (within 90
days before pretreatment period day 1) history of pregnancy, with a history of regular
menstrual cycles (21 to 35 days in duration).

Inclusion Criteria - Postmenopausal Women

- Aged 35 to 65 years, menopause may be natural or due to surgery, natural amenorrhea
must have begun by age of 55 years and have initiated at least 6 months before study
day 1.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Women with hysterectomy or complex or simple ovarian cysts greater than 3 cm in
diameter.

- History of drug abuse (within 6 months) or alcoholism (within 12 months).

- History of female infertility.

NCT00543790
Pfizer
Completed
Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Uterine Cervical Neoplasms
Irinotecan Study For Cervical Cancer
NCT00136955
Females
18+
Years
Multiple Sites
Uterine Leiomyomata (Fibroids)
Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 in Japanese Postmenopausal Women
NCT00826436
Females
35+
Years
Kagoshima,
Uterine Leiomyomata (Fibroids)
Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women
NCT00543790
Females
18+
Years
Multiple Sites
Uterine Leiomyomata (Fibroids)
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females
NCT00444704
Females
20+
Years
Tsukuba, Ibaraki Prefecture
Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women
A Randomized, Placebo-Controlled, Double-Blind, Sponsor-Unblinded, Multiple-Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PRA-027 Administered Orally To Cycling Or Postmenopausal Women
This is the first multiple-dose study in humans with PRA-027. This study will provide an assessment of the safety, tolerability, pharmacokinetics (how the drug is absorbed, metabolized and excreted by the body) and pharmacodynamics (a measure of whether the drug is active in the body) of PRA-027 after administration of 28 days of oral doses in women of childbearing potential (cycling) or postmenopausal women.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Uterine Leiomyomata (Fibroids)
Drug: PRA-027
PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
Experimental: 1
Intervention: Drug: PRA-027
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
December 2008
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Inclusion Criteria - All Women

  • Healthy, nonsmoker or smoker of fewer than 10 cigarettes (half a pack) per day and able to abstain from tobacco throughout all times when in the clinical facility.

Inclusion Criteria - Cycling Women

  • Aged 18 to 45 years, must not be breastfeeding, pregnant, or have a recent (within 90 days before pretreatment period day 1) history of pregnancy, with a history of regular menstrual cycles (21 to 35 days in duration).

Inclusion Criteria - Postmenopausal Women

  • Aged 35 to 65 years, menopause may be natural or due to surgery, natural amenorrhea must have begun by age of 55 years and have initiated at least 6 months before study day 1.

Exclusion Criteria:

  • Women with hysterectomy or complex or simple ovarian cysts greater than 3 cm in diameter.
  • History of drug abuse (within 6 months) or alcoholism (within 12 months).
  • History of female infertility.
Sexes Eligible for Study: Female
18 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00543790
3208A1-1001
B2531001
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
October 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now